Randomised double-blind placebo-controlled study of lisdexamfetamine for the treatment of methamphetamine dependence

Name & Contact Details Role Research Program Location
  • Principal Investigator: Nicholas Lintzeris, University of Sydney
  • Chief Investigator: Robert Ali, University of Adelaide
  • Chief Investigator: Adrian Dunlop, Hunter New England LHD
  • Chief Investigator: Nadine Ezard, St Vincent's Hospital Sydney
  • Chief Investigator: Jason White, University of South Australia
  • Chief Investigator: Raimondo Bruno, University of Tasmania
  • Chief Investigator: Andrew Carr, St Vincent's Centre for Applied Medical Research
  • Chief Investigator: Kate Dolan, University of New South Wales

Ezard, N., Dunlop, A., McKetin, R., Bruno, R., Ali, R., L., Carr, A., White, J., Clifford, B., Hall, M., Liu, Z., Shanahan, M., Dolan, K. and Lintzeris, N. (2018). LiMA: a study protocol for a randomised, double blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. BMJ Open. DOI: 10.1136/bmjopen-2017-020723 [RJ1438] View web page